TOP 100 MEDICAL SITES
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cord Blood America Files First Quarter 2010 Financial Results (PR Newswire) Cord Blood America, Inc. , the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, announced today that it has filed its Form 10-Q for the first quarter ended March 31, 2010 with the U.S. us.rd.yahoo.com |
PPD Rated One of Top CROs in Europe in 2010 (Business Wire) WILMINGTON, N.C.----PPD, Inc. today announced it has been rated one of Europe’s top contract research organizations in the 2010 CenterWatch European Site Survey. The company earned a number two ranking among CROs with 78.4 percent of participants rating PPD’s overall relationship quality as “excellent†or “good.†us.rd.yahoo.com |
Emergent BioSolutions Inc. Q2 2010 Earnings Call Transcript Emergent BioSolutions Inc. (EBS)Q2 2010 Earnings Call TranscriptAugust 5, 2010 5:00 pm ETComplete Story » seekingalpha.com |
Cypress Risks Deepening Disquiet With Another Spending Spree EP Vantage submits:One could be forgiven for thinking it rather provocative that a board under fire for an apparently misguided license deal should go straight out and strike two more. Perhaps a sign of single mindedness is exactly the message that Cypress Bioscience (CYPB) is trying to send to its activist hedgefund shareholder, Ramius.After Cypress’ share price halved in value to $2.16 in the wake of a licensing deal over BioLineRx’s antipsychotic CYP-1020 (BL-1020) in June, Ramius ramped up its vociferous calls for change and offered to buy the company for $4 per share, rather than see more money wasted (Ramius fires warning shot across Cypress’s bow, July 20, 2010). Rather than negotiate, Cypress has bought rights to two early-stage projects, Alexza Pharmaceuticals’ (ALXA) Staccato nicotine drug delivery platform, and autism drug carbetocin from Marina Biotech. Some analysts reckon these deals signal Cypress’ intention to press ahead unabated. The question for shareholders is whether this is a viable vision for the future.Complete Story » seekingalpha.com |
Glaxo Subpoenaed On Avandia in U.S. GlaxoSmithKline said net profit fell 3.5% in the third quarter, and disclosed that it has been subpoenaed by U.S. authorities examining its diabetes drug Avandia. online.wsj.com |